-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Laninamivir octanoate
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/203120-46-1.gif)
Category | Influenza Virus |
CAS | 203120-46-1 |
Description | Laninamivir octanoate, a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with superior anti-influenza virus activity. |
Product Information
Synonyms | 5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid 9-octanoate; (2R,3R,4S)-3-Acetamido-4-guanidino-2-[(1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-Acetamido-4-guanidino-6-[(1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl]-5,6-dihydro-4H-pyran-2-carboxylic acid; CS 8958 |
IUPAC Name | (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid |
Molecular Weight | 472.53 |
Molecular Formula | C21H36N4O8 |
Canonical SMILES | CCCCCCCC(=O)OCC(C(C1C(C(C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O |
InChI | InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1 |
InChIKey | UKTIJASCFRNWCB-RMIBSVFLSA-N |
Purity | ≥98% (HPLC) |
Density | 1.4±0.1 g/cm3 |
Solubility | DMSO: 95 mg/mL (201.04 mM); Ethanol: 5 mg/mL (10.58 mM); Water: Insoluble |
Appearance | Solid powder |
Storage | Powder: 3 years -20°C; In solvent: 2 years -80°C |
Complexity | 723 |
Exact Mass | 472.25331412 |
Index Of Refraction | 1.572 |
In Vitro | Laninamivir octanoate (CS-8958) shows inhibitory activity with an IC50 of 631-1170 nM, 39.2-221 nM and 128 nM to the H1N1 viruses strains, H3N2 viruses strains and H2N2 (A/Singapore/1/57) virus, respectively. |
In Vivo | Laninamivir octanoate (CS-8958; 95 μg/kg; intranasal administration; three dose; at 4 h before and 4 h and 17 h postinfection) treatment shows significantly life-prolonging effect in infected model. |
Target | Influenza Virus |
XLogP3-AA | 0.4 |
Description of First Aid Measures
Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.
Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.
InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.
IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.